The US FDA approved Akeega and Talvey late last week. Phase 3 trials validated Akeega's use in the treatment of patients with BRCA-positive prostate cancer. Talvey is authorized for patients with heavily pretreated multiple myeloma.
Roquette, a French-based multinational provider of pharmaceutical and nutraceutical excipients, has opened a new Pharmaceutical Innovation Center near Philadelphia in Pennsylvania, USA, complementing its other centers in France and Singapore.
Bayer is looking to spend $1 billion on drug research and development in the United States during 2023 as part of a plan to double its sales in the country by the end of the decade.
Clean Cells, part of France’s Clean Biologics group, which provides biopharmaceutical product quality control services and manufactures starting materials, has begun analytical activities at its new €22 million facility in Montaigu-Vendée, near Nantes.
Leading international distributor Brenntag has acquired the life science business of Ravenswood, strengthening its position in the Australian and New Zealand specialties market. The deal is expected to close next month.
Ineos Enterprises has agreed to acquire Ashta Chemicals from Bigshire Mexico for an undisclosed sum. The deal that includes a 100,000 kg/y potassium hydroxide (KOH) and a 65,000 t/y chlorine plant, is targeted to close before the end of 2022, subject to regulatory approvals.
US life sciences company Cytiva has acquired Germany’s Cevec Pharmaceuticals, a move Cytiva said would further strengthen its leading position in biomanufacturing solutions. Financial terms were not revealed.
US specialty materials manufacturer Aceto and 10 other companies with business operations in North America, Europe, India and China have merged into a new cross-industry player called Actylis, under the umbrella of private equity investor New Mountain Capital.
Chinese contract research, development and manufacturing organization WuXi STA, a subsidiary of WuXi AppTec, has broken ground on a new pharmaceutical campus in Middletown, Delaware, USA.
The Life Science business segment of German pharmaceuticals, chemicals and life sciences group Merck has widened its US plant for high-potent active pharmaceutical ingredients (HPAPIs) at Verona, near Madison, Wisconsin to 6,500 m2.
WeylChem’s Custom Manufacturing division has a strong record of accomplishments operating in markets such as Pharma, Agro and Pigments.
